Carpal Tunnel Release Systems Market Size

Carpal Tunnel Release Systems Market Analysis

The carpal tunnel release systems market is projected to register a CAGR of 4.9% during the forecast period.

The COVID-19 pandemic had a significant impact on the growth of the market studied. According to a Clarity Medical article published in February 2022, carpal tunnel syndrome, dry eye syndrome, repetitive stress injuries, cervical spondylitis, and sleep disorders are common, affecting nearly 30% of those working from home for the first time. Thus, the high incidence of carpal tunnel syndrome during the pandemic had a significant impact on the market. As per an NCBI article published in August 2021, peripheral microangiopathy involving nerve supply, viral demyelination, or an immune-mediated irritating antigenic stimulus on synovial sheaths after COVID-19 infection may all induce a carpal, cubital, or tarsal tunnel syndrome of the variable entity in genetically predisposed subjects associated with myxoid nerve degeneration. According to the source mentioned above, carpal tunnel syndrome may result in reactive arthritis after COVID-19 infection recovery due to irritation and, in turn, requiring decompressive surgery. These factors are expected to have a significant impact on the market during the COVID-19 pandemic.

Carpal tunnel syndrome (CTS) is a collection of characteristic symptoms and signs following compression of the median nerve within the carpal tunnel. Factors driving the market's growth are the increasing prevalence of CTS, lower procedure costs, and improved medical reimbursement coverage for CT surgeries. According to an Up-to-date article published in August 2021, carpal tunnel syndrome is a common disorder with an estimated prevalence of 1% and 5% among the general population. CTS is more frequent in females, with a female-to-male ratio of 3 to 1. In a Mayo Clinic article published in February 2022, CTS is an entrapment neuropathy caused by compression of the median nerve as it travels through the wrist's carpal tunnel. It is the most common nerve entrapment neuropathy, accounting for 90% of all neuropathies. In the United States, CTS has an incidence of 1 to 3 persons per 1000 per year, with a prevalence of 50 per 1000, with similar incidence and prevalence in most developed countries. Carpal tunnel syndrome does not cause mortality but can lead to irreversible median nerve damage, with severe loss of hand function, if not treated. Therefore, the prevalence of carpal tunnel syndrome among the global population is expected to contribute to the growth of the market.

However, a lack of awareness about CTS in developing nations and expensive surgical procedures are anticipated to impede the expansion of market participants.